Ryuvidine

Key Product Details

Product Description

Ryuvidine is an inhibitor of SETD8 protein lysine methyltransferase (PKMT) (IC₅₀ = 0.5 μM); suppresses H4K20 monomethylation in vitro. Also inhibits cyclin-dependent kinase (CDK) 4 (IC₅₀ = 6.0 μM at CDK4/cyclin D1). Induces S phase accumulation in HEK293T cells. Cytotoxic against a range of human cancer cells.

Product Specifications for Ryuvidine

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for Ryuvidine

The following data is based on the product molecular weight 284.33.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.2 mM	17.59 mL	87.93 mL	175.85 mL
1 mM	3.52 mL	17.59 mL	35.17 mL
2 mM	1.76 mL	8.79 mL	17.59 mL
10 mM	0.35 mL	1.76 mL	3.52 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Blum Small-molecule inhibitors of SETD8 with cellular activity. ASC.Chem.Biol. [Epub ahead of print] 2014 PMID: 25137013
• Ryu 5-Arylamino-2-methyl-4,7-dioxobenzothiazoles as inhibitors of cyclin-dependent kinase 4 and cytotoxic agents. Bioorg.Med.Chem.Lett. 2000 PMID: 10743948

Product Documents for Ryuvidine